§ 4606. Brand certification
If the prescriber has determined that the generic equivalent of a drug or the interchangeable biological product for the biological product being prescribed has not been effective or with reasonable certainty is not expected to be effective in treating the patient’s medical condition or causes or is reasonably expected to cause adverse or harmful reactions in the patient, the prescriber shall indicate “brand necessary,” “no substitution,” “dispense as written,” or “DAW” in the prescriber’s own handwriting on the prescription blank or shall indicate the same using electronic prescribing technology and the pharmacist shall not substitute the generic equivalent or interchangeable biological product. If a prescription is unwritten and the prescriber has determined that the generic equivalent of the drug or the interchangeable biological product for the biological product being prescribed has not been effective or with reasonable certainty is not expected to be effective in treating the patient’s medical condition or causes or is reasonably expected to cause adverse or harmful reactions in the patient, the prescriber shall expressly indicate to the pharmacist that the brand-name drug or biological product is necessary and substitution is not allowed and the pharmacist shall not substitute the generic equivalent drug or interchangeable biological product. (Added 1977, No. 127 (Adj. Sess.), § 1; amended 2001, No. 63, § 124; 2009, No. 103 (Adj. Sess.), § 4; 2017, No. 193 (Adj. Sess.), § 3.)
Structure Vermont Statutes
Chapter 91 - Prescription Drug Cost Containment
§ 4605. Alternative drug or biological product selection
§ 4622. Evidence-based education program
§ 4631. Confidentiality of prescription information
§ 4631a. Expenditures by manufacturers of prescribed products
§ 4632. Disclosure of allowable expenditures and gifts by manufacturers of prescribed products
§ 4633. Pharmaceutical marketer price disclosure
§ 4634. Prescription drug price disclosure
§ 4635. Prescription drug cost transparency
§ 4636. Impact of prescription drug costs on health insurance premiums; report
§ 4637. Notice of introduction of new high-cost prescription drugs
§ 4651. Wholesale importation program for prescription drugs; design
§ 4652. Monitoring for anticompetitive behavior